首页> 外文OA文献 >TRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study

【2h】

TRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study

机译：胜利：患者（PTS）在肿瘤组织或循环肿瘤DNA（CTDNA）中的转移结直肠癌（MCRC）患者（PTS）患者（PTS）中患者（PTS）中患者（PTS）中的术治疗（PT）和Pertuzumab（P）的主要疗效：Gozila Sub-Chinal

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Y. Nakamura; W. Okamoto; T. Kato; H. Hasegawa; K. Kato; S. Iwasa; T. Esaki; Y. Komatsu; T. Masuishi; T. Nishina; S. Nomura; M. Fukui; S. Matsuda; A. Sato; S. Fujii; J.I. Odegaard; S. Olsen; T. Yoshino;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Pertuzumab (P) plus high-dose trastuzumab (H) for the treatment of central nervous system (CNS) progression after radiotherapy (RT) in patients (pts) with HER2-positive metastatic breast cancer (MBC): Primary efficacy analysis results from the phase II PATRICIA study [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：pertuzumab（p）加上高剂量曲妥珠单抗（h）用于治疗患者（pts）中的放射治疗（pts）后的中枢神经系统（CNS）进展，HER2阳性转移性乳腺癌（MBC）：主要疗效分析结果第II期Patricia研究
2. A Phase II, Randomized, Double-Blind, Placebo-Controlled Registration Trial to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxe! in Patients With Previously Untreated HER2-Positive Metastatic Breast Cancer (CLEOPATRA) [J] . Clinical advances in hematology & oncology: H&O . 2012,第Suppla2期

机译：II期，随机，双盲，安慰剂对照的注册试验，用于评估帕妥珠单抗+曲妥珠单抗+多西他赛与安慰剂+曲妥珠单抗+多西他赛的疗效和安全性！未经治疗的HER2阳性转移性乳腺癌（CLEOPATRA）患者中
3. HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer [J] . Hitomi Sakai, Junji Tsurutani, Tsutomu Iwasa, Breast cancer . 2018,第5期

机译：循环肿瘤DNA中的HER2基因组扩增和雌激素受体阳性预示着HER2阳性转移性乳腺癌患者对曲妥珠单抗Emtansine（T-DM1）的主要耐药性
4. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
5. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial [O] . Andrea Sartore-Bianchi, Sara Lonardi, Cosimo Martino, 2020

机译：Hertuzumab和Trastuzumab Omtansine患有Her2扩增转移性结肠直肠癌的患者：II期Heracles-B试验
6. Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC) [O] . R.B. Corcoran, T. André, T. Yoshino, 2016

机译：疗效和循环肿瘤DNA（CTDNA）分析BRAF抑制剂DABRAFENIB（D），MEK抑制剂TRAMETINIB（T），患者（PTS）中的抗EGFR抗体Panitumumab（P），BRAF V600E突变（BRAFM）转移性结直肠癌（MCRC）
7. Phase II Study of a HER-2/neu (HER2) Intracellular Domain (ICD) Peptide- Based Vaccine Administered to Stage IIIB and IV HER2 Positive Breast Cancer Patients Receiving Trastuzumab Monotherapy; Annual rept. 27 Apr 2007-26 Apr 2008 [R] . Disis, M. L. 2008

机译：对接受曲妥珠单抗单一疗法的IIIB和IV期HER2阳性乳腺癌患者施用HER-2 / neu（HER2）细胞内结构域（ICD）基于肽的疫苗的II期研究;年度报告。 2007年4月27日至2008年4月26日

TRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study

著录项

引文网络

相似文献

相关主题

期刊订阅